Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
8740168 | Journal of Hospital Infection | 2018 | 20 Pages |
Abstract
ILαD could be a promising solution against staphylococcal infections as it is effective, does not promote the development of resistant strains, and in-vitro testing indicates that it may be safer than PVP-I. Further studies are justified to determine whether ILαD overcomes the clinical limitations of PVP-I.
Related Topics
Life Sciences
Immunology and Microbiology
Applied Microbiology and Biotechnology
Authors
A.P. Zisi, M.K. Exindari, E.K. Siska, G.G. Koliakos,